Incyte Correlations

INCY Stock  USD 61.44  1.25  1.99%   
The current 90-days correlation between Incyte and CytomX Therapeutics is 0.13 (i.e., Average diversification). The correlation of Incyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Incyte Correlation With Market

Average diversification

The correlation between Incyte and NYA is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and NYA in the same portfolio, assuming nothing else is changed.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.

Moving together with Incyte Stock

  0.84LLY Eli LillyPairCorr
  0.64PFE Pfizer Inc Financial Report 6th of August 2024 PairCorr
  0.7LPCN LipocinePairCorr
  0.62MOLN Molecular Partners TrendingPairCorr
  0.63BGXX Bright Green CorpPairCorr

Moving against Incyte Stock

  0.62DMTK DermTechPairCorr
  0.59ACRV Acrivon TherapeuticsPairCorr
  0.54MYMD MyMD PharmaceuticalsPairCorr
  0.48FLGC Flora Growth CorpPairCorr
  0.36INMB INmune BioPairCorr
  0.33BMY Bristol Myers SquibbPairCorr
  0.81ANEB Anebulo Pharmaceuticals Fiscal Year End 18th of September 2024 PairCorr
  0.77DYNT Dynatronics Fiscal Year End 26th of September 2024 PairCorr
  0.52TOVX Theriva BiologicsPairCorr
  0.43GCTK GlucoTrackPairCorr
  0.4CMND Clearmind Medicine CommonPairCorr
  0.38ANIX Anixa Biosciences Fiscal Year End 21st of January 2025 PairCorr
  0.38ANVS Annovis BioPairCorr
  0.35AQST Aquestive Therapeutics Earnings Call TodayPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations   
QNRXSPRO
SNTISPRO
BOLTSABS
QNRXACHL
SNTITIL
QNRXSNTI
  
High negative correlations   
SABSASMB
BOLTASMB
SNTIASMB
ASMBSPRO
QNRXASMB
ASMBTIL

Risk-Adjusted Indicators

There is a big difference between Incyte Stock performing well and Incyte Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Incyte's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CTMX  7.18  1.17  0.12 (0.53) 8.08 
 3.79 
 266.04 
TIL  1.79 (0.33) 0.00 (0.64) 0.00 
 3.53 
 9.26 
SPRO  2.09 (0.49) 0.00 (0.53) 0.00 
 3.87 
 15.04 
ASMB  2.34  0.34  0.10  0.35  3.11 
 5.11 
 17.41 
ACHL  2.55 (0.21) 0.00 (0.10) 0.00 
 5.04 
 33.40 
NXTC  5.04  0.07  0.01 (10.99) 5.79 
 13.10 
 32.48 
SNTI  4.50 (0.44) 0.00  3.15  0.00 
 8.11 
 26.47 
SABS  3.66 (1.01) 0.00  1.57  0.00 
 5.86 
 23.24 
QNRX  2.83 (0.63) 0.00 (0.38) 0.00 
 6.85 
 20.12 
BOLT  2.94 (0.42) 0.00  1.08  0.00 
 7.14 
 51.88 

Incyte Corporate Management

Thomas TrayChief FinanceProfile
Pamela MurphyVice CommunicationsProfile
Paula SwainExecutive ResourcesProfile
Christine ChiouHead RelationsProfile
Michael MorrisseyExecutive OperationsProfile
PharmD MBAExecutive AmericaProfile